Aclaris Therapeutics, Inc. (ACRS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Aclaris Therapeutics, Inc. (ACRS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 34/100 — a percentile rank of Aclaris Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $774.3M |
| P / S | 94.2× |
| EV / EBITDA | -8.8× |
| Gross margin | 79.5% |
| Operating margin | -1050.2% |
| Net margin | -921.5% |
| Return on equity | -60.8% |
| ROIC | -81.9% |
| Revenue growth | -51.0% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Aclaris Therapeutics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Aclaris Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact